| |
GenScript, the number one global provider of gene synthesis services, is playing a key role in accelerating the response to the recent Zika virus outbreak by rush delivering DNA constructs to governmental agencies and research institutions. The DNA constructs are being used for the development of a vaccine against the virus.
The Zika virus is transmitted by primarily through the bite of the Aedes mosquito. Since 2015 viral infections have been on the rise, with the most recent cases appearing in numerous countries across the Americas. Infections are largely symptomless; however evidence suggests that Zika infections in pregnant women are linked to the development of microcephaply, a neurodevelopmental disorder, in their newborns. Currently there is no vaccine or treatment for Zika, and the best preventative action is to take precautions to avoid Aedes bites.
“Time is of the essence when facing the outbreak of a virus like Zika. It’s important to be able to deliver the bioreagents that researchers need for vaccine development with high quality and rapid speed,” said GenScript Senior Service Marketing Manager, Heidi Huang, Ph.D. “That’s why we developed express gene synthesis technologies that can deliver DNA constructs in as few as four business days, the fastest turnaround time in the industry. It helps researchers decrease vaccine development time and significantly improve their response time to pandemics, saving lives in the process”.
GenScript has a history of providing DNA constructs to researchers at record speed during times of viral outbreak. In response to an H7N9 outbreak in 2013, the company delivered DNA constructs that encoded key vaccine proteins to a clinical vaccine company in just six business days. The constructs were used to expedite the development of an H7N9 vaccine that was ready for pre-clinical trials in just 28 days, less than six weeks after initial reports of H7N9 infections.
About GenScript
GenScript (genscript.com) is a world leader in gene synthesis and a peptide, protein, and antibody research partner for fundamental life science research, translational biomedical research, early stage biopharmaceutical development, and synthetic biology. Since its founding in 2002, GenScript has provided services and products to scientists in more than 100 countries worldwide. The company delivers biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, in vitro and in vivo pharmacology and industrial synthetic biology products.
Forward-Looking Statement Disclaimer
This press release contains forward-looking statements, including, without limitation, statements related to the earning and sales forecasts. These forward-looking statements are based upon GenScript’s current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: market condition, global stability, new technologies. The forward-looking statements made in this press release speak only as of the date of this press release. GenScript expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in GenScript’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contact: Karl Schmieder - messagingLAB
P: 646-515-3392 - E: genscript[.]messaginglab.com.
|
sally.wang[.]genscript.com 
